Alekhya Thirunahari
To control the motor and non-motor symptoms of Parkinson's disease, pharmacologic treatments (levodopa therapy [LVT]; dopamine agonists; MAO-B inhibitors; and COMPT-inhibitors) remain the frontline treatment choices (PD). Treatment with dopaminergic agents, especially agonist therapies (ATs), can, however, cause pernicious behavioural syndromes in some patients, which are classified as Impulse Control Disorders (ICDs) in the DSM-IV.
